Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer's Disease Progression
In overall population, co-primary endpoints of ADAS-Cog11 and ADCS-ADL were not met
Pre-specified subgroups representing up to half of the participants based on P. gingivalis infection level showed approximately 50% slowing of cognitive decline
Clinical data validated upstream mechanism of action and benefits of targeting P. gingivalis
Additional top-line GAIN Trial results to be presented at CTAD 2021 on November 11th
Cortexyme to host investor conference call today Tuesday, October 26th at 4:30 p.m. Eastern Time
Cortexyme, Inc. (NASDAQ:CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat
